Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
Continuous infusion of vancomycin was evaluated against experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Animals were infected with hVISA PC1 (vancomycin MIC, 2 mg/liter) or VISA PC3 (vancomycin MIC, 8 mg/liter) and treated for 5 days with constant serum levels of 20 or 40 mg/liter. Vancomycin continuous infusion was unsuccessful, as 20 mg/liter was barely active against PC1 (6 of 13 sterile vegetations) and 40 mg/liter failed against PC3 (2 of 9 sterile vegetations).
Department of Fundamental Microbiology, Biophore-University of Lausanne, Lausanne, Switzerland. jose.entenza@unil.ch
J M
JM
Entenza
T R
TR
Veloso
J
J
Vouillamoz
M
M
Giddey
P
P
Moreillon
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004696:Endocarditis / Q000188:drug therapy* / Q000382:microbiology; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000472:pathogenicity*; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use*; D020713:Vancomycin Resistance
D000900:Anti-Bacterial Agents; D014640:Vancomycin